The Biggest Indian Pharma Deal of the Decade

India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold ...  Show more

Anthropic refused the Pentagon unrestricted access to its Claude AI, and the fallout reshaped the tech-defense landscape overnight. OpenAI rushed in to fill the void, signing a classified deal that triggered internal resignations and a user exodus toward Claude. Host Himanshi Loh ...  Show more

Join hosts Kate Moody and Dave Morris, along with some great guests as we discuss the biggest fintech and financial services news this week. Topics covered include: New PensionBee research for Pensions Awareness Week reveals less than 15% of Brits know how much they have in pensi ...  Show more

Join hosts Laura Watkins and Benjamin Ensor alongside some great guests as we look at the biggest financial services and fintech stories of the past week. Topics covered include: a LATAM fintech roundup featuring news from Nubank, Ualá, and Tako; Klarna announcing plans to IPO i ...  Show more

About this episode: Host Benjamin Ensor, Director of Research and Strategy at 11:FS, is joined by a fantastic panel of guests as we dive into some of the biggest stories from the worlds of fintech, banking, and wider financial services this week. Stories covered on the podcast th ...  Show more

There aren’t many Ivy League professors as bold as Dave Collum. It’s amazing he still has a job. (00:00) How Collum Predicted the 2008 Financial Crisis (11:00) Collum’s Mission to Uncover the Truth About Covid (19:36) Government Experiments Being Conducted on Foster Care Children ...  Show more